

BASIC RESEARCH

# Interleukin-1 beta up-regulates tissue inhibitor of matrix metalloproteinase-1 mRNA and phosphorylation of c-jun N-terminal kinase and p38 in hepatic stellate cells

Ya-Ping Zhang, Xi-Xian Yao, Xia Zhao

Ya-Ping Zhang, Xi-Xian Yao, Xia Zhao, Department of Gastroenterology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China

Correspondence to: Professor Xi-Xian Yao, Department of Gastroenterology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.

gracezhangyaping@yahoo.com.cn Telephone: +86-311-87814356

Received: 2005-10-21 Accepted: 2005-11-10

#### Abstract

AIM: To study the relationship between interleukin-1beta (IL-1 $\beta$ ) up-regulating tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) mRNA expression and phosphorylation of both c-jun N-terminal kinase (JNK) and p38 in rat hepatic stellate cells (HSC).

METHODS: RT-PCR was performed to measure the expression of TIMMP-1 mRNA in rat HSC. Western blot was performed to measure IL-1 $\beta$ -induced JNK and p38 activities in rat HSC.

RESULTS: TIMMP-1 mRNA expression  $(1.191 \pm 0.079)$ was much higher after treatment with IL-1β (10 ng/mL) for 24 h than in control group  $(0.545 \pm 0.091)$  (*P*<0.01). IL-1β activated JNK and p38 in a time-dependent manner. After stimulation with IL-1\beta for 0, 5, 15, 30, 60 and 120 min, the JNK activity was  $0.982 \pm 0.299$ ,  $1.501 \pm 0.720$ ,  $2.133 \pm 0.882$ ,  $3.360 \pm 0.452$ ,  $2.181 \pm 0.789$ , and 1.385 ± 0.368, respectively. There was a significant difference in JNK activity at 15 min (P<0.01), 30 min (P<0.01) and 60 min (P < 0.01) in comparison to that at 0 min. The p38 activity was  $1.061 \pm 0.310$ ,  $2.050 \pm 0.863$ ,  $2.380 \pm 0.573$ ,  $2.973 \pm 0.953$ ,  $2.421 \pm 0.793$ , and  $1.755 \pm 0.433$  at the 6 time points (0, 5, 15, 30, 60 and 120 min) respectively. There was a significant difference in p38 activity at 5 min (P<0.05), 15 min (P<0.01), 30 min (P < 0.01) and 60 min (P < 0.01) compared to that at 0 min. TIMMP-1 mRNA expression trended to decrease in 3 groups pretreated with different concentrations of SP600125 (10 μmol/L, 1.022 ± 0.113; 20 μmol/L,  $0.869 \pm 0.070$ ; 40  $\mu$ mol/L,  $0.666 \pm 0.123$ ). Their decreases were all significant (P < 0.05, P < 0.01, P < 0.01) in comparison to control group (without SP600125 treatment,  $1.163 \pm 0.107$ ). In the other 3 groups pretreated

with different concentrations of SB203580 (10 µmol/L,  $1.507\pm0.099$ ; 20 µmol/L,  $1.698\pm0.107$ ; 40 µmol/L,  $1.857\pm0.054$ ), the expression of TIMMP-1 mRNA increased. Their levels were higher than those in the control group (without SB203580 treatment,  $1.027\pm0.061$ ) with a significant statistical significance (P<0.01).

CONCLUSION: IL-1 $\beta$  has a direct action on hepatic fibrosis by up-regulating TIMMP-1 mRNA expression in rat HSC. JNK and p38 mitogen-activated protein kinases (MAPKs) are involved in IL-1 $\beta$ -induced TIMMP-1 gene expression, and play a distinct role in this process, indicating that p38 and JNK pathways cooperatively mediate TIMP-1 mRNA expression in rat HSC.

© 2006 The WJG Press. All rights reserved.

**Key words:** TIMMP-1; JNK; p38; Signal transduction; Interleukin-1β; Hepatic stellate cells

Zhang YP, Yao XX, Zhao X. Interleukin-1 beta up-regulates tissue inhibitor of matrix metalloproteinase-1 mRNA and phosphorylation of c-jun N-terminal kinase and p38 in hepatic stellate cells. *World J Gastroenterol* 2006; 12(9): 1392-1396

http://www.wjgnet.com/1007-9327/12/1392.asp

# INTRODUCTION

Hepatic fibrosis is a common consequence of chronic liver disease and results from the activation of hepatic stellate cells (HSC). After liver tissue damage, HSC undergo a transition from quiescent to activated phenotypes and increase proliferation and synthesis of extracellular matrix (ECM)<sup>[1-4]</sup>. Activated HSC express matrix metalloproteinases (MMPs), the key enzyme in the degradation of ECM, but also expresses the tissue inhibitors of matrix metalloproteinases (TIMMPs). Many cytokines may affect the activation of HSCs and regulate the secretion of MMPs and TIMMPs<sup>[5,6]</sup>.

Mitogen-activated protein kinase (MAPK) plays an important role in the transduction of extracellular signals to the nuclei<sup>[7,8]</sup>. Four groups of mammalian MAPK-family have been characterized, namely extracellular signal-regulated kinases (ERK), c-jun N-terminal kinase (JNK),

p38 and ERK5. Studies indicate that JNK and p38 are essential members of MAPK supper family and play a role in the responses of HSC to hepatic injury and inflammation [9,10]. JNK and p38 are activated by lipopolysaccharide endotoxin (LPS), tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-1 (IL-1). Activated JNK translocates to the nuclei, activates transcription factors and involves a wide range of cellular events, including cell proliferation, differentiation and apoptosis [11,12].

IL-1 is a pro-inflammatory cytokine that has a key role both in the inflammatory response and in autoimmune diseases [13-17]. Although HSC activation is insufficiently documented, IL-1 is accepted as a potent cytokine for fibrosis of other organs such as the heart, gingival tissue, and kidney [15,18,19]. Recent findings suggest that activation of MAPKs participates in intracellular signaling events induced by IL-1. In this study, we demonstrated the relationship between effects of interleukin-1 $\beta$  upregulating TIMMP-1 mRNA expression and MAPK signal transduction in rat HSC.

# **MATERIALS AND METHODS**

#### Reagents

RPMI 1640 was purchased from GIBCO BRL. SP600125, SB203580 and HEPES were purchased from Sigma Chemicals International. IL-1β was obtained from PeproTech INC. Mouse anti-phospho-JNK antibody and mouse anti- phospho-p38 antibody were purchased from Santa Cruz Company. Rabbit anti-β-actin polyclonal antibody was obtained from Zhongshan Company. RNasin was purchased from Promega Company.

#### Cell culture of rat HSC


HSC cell line (CFSC) was established and presented by Professor Greenwell, Marion Bessin Liver Research Center, Albert Einstein College of Medicine. The phenotype of CFSC was activated HSC obtained from CCl<sub>4</sub>-induced cirrhotic liver of rats after spontaneous immortalization in culture. Cells were seeded and grown at 37°C in 50 mL/L CO<sub>2</sub> RPMI 1640 supplemented with 10% fetal calf serum (FCS), 4 mmol/L L-glutamine, 1 mmol/L HEPES and 100 U/mL penicillin/streptomycin. When the cells were 80%-90% confluent, HSC were serum-starved in medium containing 1% FCS for 12 h. HSC of IL-1β groups were treated with IL-1β (10 ng/mL) for 24 h, but HSC of control group were treated with nothing, then TIMMP-1 mRNA expression in rat HSC was examined. After stimulation with IL-1 $\beta$  (10 ng/mL) for 0, 5, 15, 30, 60, and 120 min, the activities of JNK and p38 were examined. To study the relationship between IL-1β up-regulating TIMMP-1 mRNA expression as well as JNK and p38 signal pathway, JNK inhibitor SP600125 and p38 inhibitor SB203580 were used to inhibit JNK and p38 activities. When HSC were pretreated for 30 min with 1% dimethyl sulfoxide (DMSO, a solvent of SP600125 and SB203580), SP600125 or SP203580 was then treated with IL-1 beta (10 ng/mL) for 24 h, and subsequently TIMMP-1 mRNA expression in rat HSC was examined. SP600125 and SB203580 were prepared as previously described<sup>[20, 21]</sup>.

# Reverse transcriptase polymerase chain reaction (RT-PCR)

RT-PCR was performed to measure the expression level of TIMMP-1 mRNA in rat HSC. The sequences of the primers used for TIMMP-1 sense and antisense are 5' -TCC CCA GAA ATC ATC GAG AC-3' (sense) and 5' -ATC GCT GAA CAG GGA AAC AC-3' (antisense), a 329 bp fragment was amplified. The sequences of the primers used for GAPDH sense and antisense are 5'-GGC CCC TCT GGA AAG CTG TG -3' (sense) and 5'-CCG CCT GCT TCA CCA CCT TCT-3' (antisense), a 239 bp fragment was amplified. Total RNA was extracted from cultured HSC using TRIzol reagent following the manufacturer's instructions. Then 2 µg RNA of each sample was reverse-transcribed using random primer and reverse transcriptase in 25 µL of volume. Subsequently PCR was carried out in 25 µL reaction mixture containing 5 µL cDNA template, 2.5 μL 10×PCR buffer, 1 μL 10 mmol/L dNTPs, 1.5 µL 15 pmol/L TIMMP-1 or GAPDH primers, 2.5 U Taq DNA polymerase. Thirty-five cycles of PCR amplification for TIMP-1 and 30 cycles of PCR amplification for GAPDH were carried out for 5 min at 94°C for initial DNA denaturation, followed by individual cycles of denaturation (at 94°C for 45 s), annealing (at 56 °C for 35 s), polymerization (at 72°C for 45 s) and then a final extension at 72°C for 5 min. PCR products were electrophoresed on 2% agarose gel, stained with ethidium bromide (EB) and quantitated using Gel-Pro Analyzer Version 3.0. The band intensity of TIMMP-1 was compared to that of GAPDH, and the amount of TIMMP-1mRNA was estimated.

#### Western blot analysis

Western blot was performed to measure IL-1\beta-induced JNK and p38 activation in rat HSC. The HSC were lysed on ice by lysis buffer containing 50 mol/L Tris-HCl (pH 7.5), 150 mol/L NaCl, 10% glycerol, 1% Nonidet P-40, 1% SDS, 0.5% deoxycholate, 1.0 mol/L PMSF, and 1 mol/L sodium orthovanadate for 30 min. The cell lysate was centrifuged at 10 000 r/min for 10 min and the supernatant was collected for Western blot analysis. Protein concentration was measured using Coomassie brilliant blue G-250 (CBB) kit following the manufacturer's instructions. Protein samples (50 µg) were subjected to 10% SDS-PAGE gel electrophoresis and then transferred onto a nitrocellulose membrane by electro-blotting. The membrane was incubated at 4 °C overnight in Tris-buffered saline/Tween 20 (20 mol/L Tris-HCl, pH 7.4, 150 mol/L NaCl, 0.05% Tween 20) with 5% nonfat milk. After blocking, the membrane was incubated for 5 h at room temperature in TBS buffer (50 mol/L Tris-HCl, 150 mol/L NaCl) containing an 1:100 dilution of mouse anti-phospho-JNK monoclonal antibody, anti-phospho-p38 monoclonal antibody or rabbit anti-β-actin polyclonal antibody. Then the membrane was incubated for 2 h at room temperature in TBS containing an 1:300 0 dilution of anti-mouse IgG (H+L)/ HRP, 1:100 0 dilution of anti-mouse IgM (H+L)/HRP or 1:300 0 dilution of anti-rabbit IgG (H+L)/HRP antibody. Specific binding of the antibody was visualized by the enhanced chemiluminescence (ECL) detection system following the manufacturer's instructions. The intensity of



**Figure 1** Expression of TIMMP-1 mRNA in HSC detected by RT-PCR. Marker: 200-600 DNA marker; lane 1: control group (without IL-1beta treatment); lane 2: IL-1 $\beta$  group (with IL-1 $\beta$  treatment)

the bands was determined by scanning video densitometry using Gel-Pro Analyzer Version 3.0. The levels of phospho-JNK protein and phospho-p38 protein were normalized to the level of  $\beta$ -actin protein.

#### Statistical analysis

1394

The data were presented as mean  $\pm$  SD. Statistical analysis was performed by the statistical software SPSS 11 using independent-sample t test and one-way ANOVA test. P < 0.05 was considered statistically significant.


#### **RESULTS**


### IL-1β up-regulated mRNA expression of TIMMP-1

We examined the mRNA expression of TIMMP-1 in rat HSC with RT-PCR. The ratio of TIMMP-1/GAPDH represented the expression of TIMMP-1 mRNA. The data showed that the TIMMP-1 mRNA expression (1.191 $\pm$ 0.079) in the group treated with IL-1 $\beta$  (10 ng/mL) for 24 h was much higher than that in the control group (0.545 $\pm$ 0.091). There was a statistical significance between the two groups (P<0.01, Figure 1).

#### IL-1β activated JNK and p38 in a time-dependent manner

After stimulation with IL-1\beta for 0, 5, 15, 30, 60 and 120 min, the activities of JNK, p38 and  $\beta$ -actin were measured. The intensity of the two bands at 46 KD and 55 KD of JNK and the band at 38 KD of p38 were compared to that of β-actin and the ratio represented JNK and p38 activity. At the 6 time points, the JNK activity was  $0.982 \pm 0.299$ ,  $1.501 \pm 0.720$ ,  $2.133 \pm 0.882$ ,  $3.360 \pm 0.452$ ,  $2.181\pm0.789$ , and  $1.385\pm0.368$ , respectively. There was a significant difference in JNK activity at 15 min (P < 0.01), 30 min (P<0.01) and 60 min (P<0.01) compared to that at 0 h. The data showed that JNK activity increased slightly after stimulation with IL-1\beta for 5 min, but the difference was not significant when compared to that at 0 h (without IL-1β treatment). An apparently increased phosphorylation of JNK was first detected at 15 min in HSC and reached its peak at 30 min after IL-1\beta treatment. The values restored to the original levels at 120 min (Figure 2). On the other hand, the p38 activity was  $1.061 \pm 0.310$ ,  $2.050 \pm$ 0.863,  $2.380 \pm 0.573$ ,  $2.973 \pm 0.953$ ,  $2.421 \pm 0.793$ , and





**Figure 2** IL-1β activates JNK and p38 in a time-dependent manner in rat HSC. **A:** Representative Western blot results of JNK and p38; **B:** Densitometry of Western blot analyzed by Gel-Pro software. n=6.  $^bP$  < 0.01 vs 0 h of JNK,  $^aP$  < 0.05 vs 0 h of p38,  $^dP$  < 0.01 vs 0 h of p38.


 $1.755 \pm 0.433$ , respectively at the 6 time points. There was a significant difference in p38 activity compared to that at 0 h, 5 min (P < 0.05), 15 min (P < 0.01), 30 min (P < 0.01) and 60 min (P < 0.01). A significant increase was first observed at 5 min and peaked at 30 min. The values restored to the original levels at 120 min (Figure 2).

# Effect of SP600125 and SB203580 on IL-1 $\beta$ -induced expression of TIMMP-1 mRNA in rat HSC

TIMMP-1 mRNA expression induced by IL-1β trended to decrease in groups pretreated with different concentrations of SP600125 (10  $\mu$ mol/L, 1.022  $\pm$  0.113; 20  $\mu$ mol/L,  $0.869 \pm 0.070$ ; 40  $\mu$ mol/L,  $0.666 \pm 0.123$ ). When the concentration of SP600125 was increased, the expression of TIMMP-1 mRNA was gradually reduced. Compared to control group (without SP600125 treatment)  $(1.163 \pm 0.107)$ , there was a significant difference (P < 0.05, P < 0.01, P < 0.01) (Figure 3). However, the expression of TIMMP-1 mRNA trended to increase in groups pretreated with different concentrations of SB203580 (10 μmol/L,  $1.507 \pm 0.099$ ; 20 µmol/L,  $1.698 \pm 0.107$ ; 40 µmol/L,  $1.857 \pm 0.054$ ). When the concentration of SB203580 was increased, the expression of TIMMP-1 mRNA increased gradually. In comparison to control group (without SB203580 treatment)  $(1.027 \pm 0.061)$ , the difference was significant (P < 0.01, Figure 3).

#### **DISCUSSION**

Hepatic fibrosis represents a repairable process of chronic hepatic damages including viral infection, toxic damage, alcohol, as well as autoimmune reactions. In response to



**Figure 3** Effect of SP600125 and SB203580 on IL-1β-induced expression of TIMMP-1 mRNA in rat HSC. **A:** Representative photos of different concentrations of SP600125 of RT-PCR; **B:** Representative photos of different concentrations of SB203580 of RT-PCR. **C:** TIMMP-1 mRNA expression in **A** and **B.** 1: IL-1β + DMSO; 2: IL-1β + SP600125 or SB203580 (10 μmol/L); 3: IL-1β + SP600125 or SB203580 (20 μmol/L); 4: IL-1β + SP600125 or SB203580 (40 μmol/L).  $n = 6.^{o}P < 0.05 \text{ vs } \text{Il-1}\beta + \text{SP600125}, ^{b}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.01 \text{ vs } \text{IL-1}\beta + \text{SP600125}, ^{d}P < 0.$ 

liver injury of any etiology, the normally quiescent HSC undergo a progressive process of trans-differentiation into  $\alpha$  smooth muscle action ( $\alpha$ -SMA) on positive myofibroblast-like cell-activated HSC. By increasing secretion of extracellular matrix proteins (TIMMP-1 and TIMMP-2), activated HSC is responsible for deposition and accumulation of the majority of excess ECM in the fibrotic liver. Furthermore, activated HSC can contribute to the fibrogenic process through their ability to secrete and respond to a wide range of cytokines and growth factors, such as IL-1, IL-6, transforming growth factor  $\beta(TGF-\beta)$  and platelet-derived growth factor (PDGF). MMPs are a family of zinc metalloendopeptidases and responsible for the turnover of all the ECM components. TIMMPs, specific inhibitors of MMPs, are the key

regulators of MMP activity and ECM degradation. Some studies have shown that TIMMP is a very important promoting factor for hepatic fibrosis and inhibits MMPs to decompose ECM. In the liver, TIMMP-1 and TIMMP-2 have been identified and TIMMP-1 plays a more important role in the pathological process of hepatic fibrosis than TIMMP-2<sup>[22-26]</sup>.

Inflammation is a key component of chronic liver disease. IL-1 is one of the major mediators regulating inflammatory response<sup>[27, 28]</sup>. There are two forms of IL-1, namely IL-1alph and IL-1beta with indistinguishable biological activities. IL-1 may be involved in hepatic fibrosis, causing hepatic tissue injury which induces the fibrotic response and participating in hepatic fibosis by promoting the deposition of ECM<sup>[5,7,29,30]</sup>. In the present study, TIMMP-1 mRNA expression after treatment with IL-1beta for 24 h was much higher than that in control group. Strong expression of TIMMP-1 inhibits the degradation of collagen by MMPs, thus promoting the deposition of ECM. The continuous deposition of ECM in the liver finally results in hepatic fibrosis, suggesting that IL-1beta has a direct action on hepatic fibrogenesis through stimulating TIMMP-1 production in activated HSC.

As we known, IL-1 could activate the MAPK cascades including ERK, p38 and JNK[31]. In 3 groups of the MAPK family, the role of ERK has been studied in  $\mathrm{HSC}^{[9,10,30,32]}$ , but the role of p38 and JNK in regulating TIMMP-1 expression in HSC is poorly understood. The aim of our study was to evaluate the effect of p38 and JNK on TIMMP-1 mRNA expression induced by IL-1beta in HSC. Our data demonstrated that following stimulation with IL-1beta, the 2 MAPK pathways including p38 and JNK were all activated. In comparison to control group (without IL-1beta treatment), phosphorylation of JNK was first detected at 15 min in HSC and reached its peak at 30 min. The values restored to original levels at 120 min. In comparison to control group (without IL-1beta treatment), a significant increase of p38 activity was first observed at 5 min for p38 peaked at 30 min. The values returned to control levels at 120 min (Figure 2). The data showed that IL-1beta could activate JNK and p38 MAPKs in a timedependent manner in rat HSC.

To study the relationship between IL-1beta up-regulating TIMMP-1 mRNA and phosphorylation of JNK and p38, JNK inhibitor SP600125 and p38 inhibitor SB203580 were used to inhibit JNK and p38 activities. Then TIMMP-1 mRNA expression in rat HSC induced by IL-1beta was observed. Our study clearly showed that blocking JNK could result in inhibition of TIMMP-1 mRNA expression in HSC, but inhibition of p38 in HSC increased TIMMP-1 mRNA expression. When the concentration of SP600125 was increased, the expression of TIMMP-1 mRNA was gradually reduced, but when the concentration of SB203580 was increased, TIMMP-1 mRNA expression increased gradually, indicating that the 2 MAPKs cooperatively modulate the TIMMP-1 mRNA expression in HSC when they are activated simultaneously by IL-1β. As a result, interaction between JNK and p38 pathways upregulates TIMMP-1 mRNA expression in rat HSC induced by IL-1beta. The signal transduction in HSC induced by IL-1beta is very complex. Following the treatment with

Number 9

IL-1beta, whether TIMP-1 has any other pathways such as JAK/STAT and PI3-K to promote hepatic fibrosis is still unknown. Further studies are needed to elucidate its mechanism

In summary, differential signal transduction pathway triggered by IL-1 $\beta$  can lead to TIMMP-1 gene upregulation in rat HSC. A better understanding of these pathways may contribute to the development of more rational therapies to counteract the devastating effects of hepatic fibrosis.

# **REFERENCES**

- Yao XX, Tang YW, Yao DM, Xiu HM. Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells. World J Gastroenterol 2002; 8: 511-514
- Yao XX, Jiang SL, Tang YW, Yao DM, Yao X. Efficacy of Chinese medicine Yi-gan-kang granule in prophylaxis and treatment of liver fibrosis in rats. World J Gastroenterol 2005; 11: 2583-2590
- 3 Yao XX, Lv T. Effects of pharmacological serum from normal and liver fibrotic rats on HSCs. World J Gastroenterol 2005; 11: 2444-2449
- 4 Wang JM, Yao XX, Li XT, Yang SL, Su Z. Effects of Radix Salviae Miltiorrhizae on Ca2+ in hepatic stellate cells. *Sichuan Daxue Xuebao Yixue Ban* 2005; **36:** 221-224
- 5 Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW, Tsukamoto H. Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 2004; 279: 4820-4828
- 6 Smart DE, Vincent KJ, Arthur MJ, Eickelberg O, Castellazzi M, Mann J, Mann DA. JunD regulates transcription of the tissue inhibitor of metalloproteinases-1 and interleukin-6 genes in activated hepatic stellate cells. J Biol Chem 2001; 276: 24414-24421
- 7 Lee HS, Miau LH, Chen CH, Chiou LL, Huang GT, Yang PM, Sheu JC. Differential role of p38 in IL-1alpha induction of MMP-9 and MMP-13 in an established liver myofibroblast cell line. J Biomed Sci 2003; 10: 757-765
- 8 Wang ZQ, Wu DC, Huang FP, Yang GY. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. *Brain Res* 2004; 996: 55-66
- 9 Svegliati-Baroni G, Ridolfi F, Di Sario A, Saccomanno S, Bendia E, Benedetti A, Greenwel P. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. *Hepatology* 2001; 33: 1130-1140
- Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. Am J Physiol 1997; 273: G804-G811
- 11 Marra F, Delogu W, Petrai I, Pastacaldi S, Bonacchi A, Efsen E, Aleffi S, Bertolani C, Pinzani M, Gentilini P. Differential requirement of members of the MAPK family for CCL2 expression by hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004; 287: G18-G26
- 12 Schnabl B, Bradham CA, Bennett BL, Manning AM, Stefanovic B, Brenner DA. TAK1/JNK and p38 have opposite effects on rat hepatic stellate cells. *Hepatology* 2001; 34: 953-963
- Huang Q, Yang J, Lin Y, Walker C, Cheng J, Liu ZG, Su B. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol 2004; 5: 98-103
- 14 Zhang B, Perpetua M, Fulmer M, Harbrecht BG. JNK signaling involved in the effects of cyclic AMP on IL-1beta plus

- IFNgamma-induced inducible nitric oxide synthase expression in hepatocytes. *Cell Signal* 2004; **16:** 837-846
- Fan JM, Huang XR, Ng YY, Nikolic-Paterson DJ, Mu W, Atkins RC, Lan HY. Interleukin-1 induces tubular epithelialmyofibroblast transdifferentiation through a transforming growth factor-beta1-dependent mechanism in vitro. Am J Kidney Dis 2001; 37: 820-831
- 16 **Parker LC**, Luheshi GN, Rothwell NJ, Pinteaux E. IL-1 beta signalling in glial cells in wildtype and IL-1RI deficient mice. *Br J Pharmacol* 2002; **136**: 312-320
- 17 **Subramaniam S,** Stansberg C, Cunningham C. The interleukin 1 receptor family. *Dev Comp Immunol* 2004; **28**: 415-428
- 18 Fernandez L, Mosquera JA. Interleukin-1 increases fibronectin production by cultured rat cardiac fibroblasts. *Pathobiology* 2002; 70: 191-196
- 19 Kida Y, Kobayashi M, Suzuki T, Takeshita A, Okamatsu Y, Hanazawa S, Yasui T, Hasegawa K. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 2005; 29: 159-168
- 20 Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 2001; 98: 13681-13686
- 21 Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364: 229-233
- 22 Zheng WD, Zhang LJ, Shi MN, Chen ZX, Chen YX, Huang YH, Wang XZ. Expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in hepatic stellate cells during rat hepatic fibrosis and its intervention by IL-10. World I Gastroenterol 2005; 11: 1753-1758
- 23 Cao Q, Mak KM, Ren C, Lieber CS. Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways. J Biol Chem 2004; 279: 4292-4304
- 24 Nie QH, Duan GR, Luo XD, Xie YM, Luo H, Zhou YX, Pan BR. Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis. World J Gastroenterol 2004; 10: 86-90
- Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res 2005; 33: 3540-3549
- 26 Chen M, Wang GJ, Diao Y, Xu RA, Xie HT, Li XY, Sun JG. Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo. World J Gastroenterol 2005; 11: 4045-4051
- 27 Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3
- 28 Janssens S, Beyaert R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem Sci 2002; 27: 474-482
- 29 **Pinzani M,** Marra F. Cytokine receptors and signaling in hepatic stellate cells. *Semin Liver Dis* 2001; **21:** 397-416
- 30 **Mann DA,** Smart DE. Transcriptional regulation of hepatic stellate cell activation. *Gut* 2002; **50:** 891-896
- Satoh M, Masamune A, Sakai Y, Kikuta K, Hamada H, Shi-mosegawa T. Establishment and characterization of a simian virus 40-immortalized rat pancreatic stellate cell line. *Tohoku J Exp Med* 2002; 198: 55-69
- 32 **Xue DY,** Hong JH, Xu LM. Salianic-acid B inhibits MAPK signaling in activated rat hepatic stellate cells. *Zhonghua Gan Zang Bing Za Zhi* 2004; **12:** 471-474
  - S- Editor Guo SY L- Editor Wang XL E- Editor Ma WH